Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

Changes in A1c and body weight were evaluated. TAKEAWAY: Tirzepatide was associated with a 42% lower risk for all-cause mortality than GLP-1 RAs (adjusted hazard ratio, 0.58; 95% CI, 0.45-0.75).

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages.

Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits Nov. 13, 2024 5:45 PM ET Eli Lilly and Company (LLY) Stock By: Jonathan Block, SA News Editor 9 Comments Play (1min) ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine, 2024; DOI: 10.1056/NEJMoa2410819 ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...